(1R,9R)-Exatecan mesylate

Synonyms: (1R,9R)-DX8951f
(1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) 是一种非前药喜树碱衍生物,作为拓扑异构酶 I 抑制剂,它通过稳定酶-DNA 可切割复合物来阻断酶活性并诱导细胞凋亡 (apoptosis),不仅能有效抑制多种恶性肿瘤细胞的增殖和肿瘤生长,还可规避 P-糖蛋白介导的多药耐药性,因而被广泛应用于胰腺癌、肺癌、乳腺癌、白血病等多种癌症的临床前研究中,其低活性异构体为 (1S,9R)-Exatecan mesylate (MS-B07407)。
产品编号: MS-H96188 纯度: 99.49% CAS No.: 2938875-39-7 分子式: C25H26FN3O7S 分子量: 531.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
询价
1g
询价
询价
5g
询价
询价

产品描述

(1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) 是一种非前药喜树碱衍生物,作为拓扑异构酶 I 抑制剂,它通过稳定酶-DNA 可切割复合物来阻断酶活性并诱导细胞凋亡 (apoptosis),不仅能有效抑制多种恶性肿瘤细胞的增殖和肿瘤生长,还可规避 P-糖蛋白介导的多药耐药性,因而被广泛应用于胰腺癌、肺癌、乳腺癌、白血病等多种癌症的临床前研究中,其低活性异构体为 (1S,9R)-Exatecan mesylate (MS-B07407)。

生物实验数据

生物活性 (1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative that acts as a topoisomerase I inhibitor by stabilizing the enzyme-DNA cleavable complex to block enzymatic activity and induce apoptosis; it not only effectively inhibits the proliferation and tumor growth of various malignant tumor cells but also circumvents P-glycoprotein-mediated multidrug resistance, and is therefore widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia, with its low-activity isomer being (1S,9R)-Exatecan mesylate (MS-B07407).
IC50 & Target

Camptothecins

 

体外研究
(In Vitro)

(1R,9R)-Exatecan mesylate 可在体外强效抑制 SUIT-2 和 KP-1N 人胰腺癌细胞系的生长,其 48 h 的 IC50 值分别为 0.079 ng/mL 和 0.12 ng/mL。

体内研究
(In Vivo)

(1R,9R)-Exatecan (mesylate) (3.125-18.75 mg/kg; i.v.; once every 4 days; 4 doses) 对裸鼠体内的 SUIT-2 胰腺癌异种移植物表现出强效的剂量依赖性抗肿瘤活性,在测试剂量范围内的肿瘤生长抑制率为 68% 至 79%。
(1R,9R)-Exatecan (mesylate) (18.75 mg/kg; i.v.; once every 4 days; 4 doses) 在最大耐受剂量下,对裸鼠体内耐 CPT-11 的 SUIT-2/CPT-11 胰腺癌异种移植物的肿瘤生长抑制率达到 72%。
(1R,9R)-Exatecan (mesylate) (2.5-10 mg/kg; i.v.; once every 5 days; 4 doses) 可剂量依赖性地抑制裸鼠体内 SUIT-2 胰腺癌的肝转移,在总剂量为 40 mg/kg 时,肝肿瘤生长评分抑制率达 78%,腹水抑制率达 100%。

Animal Model: BALB/c-nu/nu (male, 6 weeks old, subcutaneous xenograft of human pancreatic carcinoma SUIT-2 cells)
Dosage: 3.125 mg/kg (total 12.5 mg/kg); 6.25 mg/kg (total 25 mg/kg); 12.5 mg/kg (total 50 mg/kg); 18.75 mg/kg (total 75 mg/kg)
Administration: i.v.; once every 4 days; 4 doses
Result: Achieved a 79% tumor growth inhibition rate with mean tumor weight of 0.154 ± 0.027 g at total dose 75 mg/kg.
Achieved a 68% tumor growth inhibition rate with mean tumor weight of 0.236 ± 0.100 g at total dose 50 mg/kg.
Achieved a 78% tumor growth inhibition rate with mean tumor weight of 0.164 ± 0.053 g at total dose 25 mg/kg.
Achieved a 68% tumor growth inhibition rate with mean tumor weight of 0.235 ± 0.057 g at total dose 12.5 mg/kg.
Caused no body weight loss in any treated group.
Animal Model: BALB/c-nu/nu (male, 6 weeks old, subcutaneous xenograft of CPT-11-resistant human pancreatic carcinoma SUIT-2/CPT-11 cells)
Dosage: 3.125 mg/kg (total 12.5 mg/kg); 6.25 mg/kg (total 25 mg/kg); 12.5 mg/kg (total 50 mg/kg); 18.75 mg/kg (total 75 mg/kg)
Administration: i.v.; once every 4 days; 4 doses
Result: Achieved a 72% tumor growth inhibition rate with mean tumor weight of 0.250 ± 0.061 g at total dose 75 mg/kg; caused maximum body weight loss of 14.6% on day 31.
Achieved a 33% tumor growth inhibition rate with mean tumor weight of 0.595 ± 0.130 g at total dose 50 mg/kg; caused maximum body weight loss of 6.1% on day 21.
Achieved a 13% tumor growth inhibition rate with mean tumor weight of 0.776 ± 0.157 g at total dose 25 mg/kg; caused maximum body weight loss of 8.7% on day 15.
Achieved a 20% tumor growth inhibition rate with mean tumor weight of 0.712 ± 0.065 g at total dose 12.5 mg/kg; caused maximum body weight loss of 3.2% on day 15.
Caused no treatment-related deaths in any group.
Animal Model: BALB/c-nu/nu (male, 6 weeks old, liver metastasis model via intrasplenic injection of human pancreatic carcinoma SUIT-2 cells)
Dosage: 2.5 mg/kg (total 10 mg/kg); 5 mg/kg (total 20 mg/kg); 10 mg/kg (total 40 mg/kg)
Administration: i.v.; once every 5 days; 4 doses
Result: Achieved a 78% liver tumor growth score inhibition rate with mean liver tumor growth score of 0.7 ± 0.9, 3/7 liver tumor incidence, mean liver weight of 1.594 ± 0.154 g, 2/7 spleen tumor incidence, 100% ascites inhibition with 0.0 ± 0.0 mL ascites volume, 0/7 ascites incidence, and 3/7 tumor-free mice at total dose 40 mg/kg.
Achieved a 69% liver tumor growth score inhibition rate with mean liver tumor growth score of 1.0 ± 0.6, 5/6 liver tumor incidence, mean liver weight of 1.594 ± 0.163 g, 2/6 spleen tumor incidence, 100% ascites inhibition with 0.0 ± 0.0 mL ascites volume, 0/6 ascites incidence, and 1/6 tumor-free mice at total dose 20 mg/kg.
Achieved a 28% liver tumor growth score inhibition rate with mean liver tumor growth score of 2.3 ± 1.1, 6/6 liver tumor incidence, mean liver weight of 1.780 ± 0.197 g, 3/6 spleen tumor incidence, 97% ascites inhibition with 0.1 ± 0.1 mL ascites volume, and 2/6 ascites incidence at total dose 10 mg/kg.
性状 固体
颜色 Gray to brown

化学信息

分子量 531.55
分子式 C25H26FN3O7S
CAS No. 2938875-39-7
别名 (1R,9R)-DX8951f

储存&溶解度

储存方式

4°C, stored under nitrogen, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 16.67 mg/mL (31.36 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8813 mL9.4065 mL18.8129 mL47.0323 mL
5 mM0.3763 mL1.8813 mL3.7626 mL9.4065 mL
10 mM0.1881 mL0.9406 mL1.8813 mL4.7032 mL
15 mM0.1254 mL0.6271 mL1.2542 mL3.1355 mL
20 mM0.0941 mL0.4703 mL0.9406 mL2.3516 mL
25 mM0.0753 mL0.3763 mL0.7525 mL1.8813 mL
30 mM0.0627 mL0.3135 mL0.6271 mL1.5677 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础